Search Results - "Drug addicts"

The Charnoly body : a novel biomarker of mitochondrial bioenergetics / by Sharma, Sushil, Ph. D., D.M.R.I.T

Table of Contents: “…Free radical-induced compromised mitochondrial bioenergetics triggers Charnoly body formation (free radical hypothesis of charnoly body formation; stages of intracellular toxification/detoxification; biomarkers of intracelular detoxification) -- Free radical-induced molecular pathophysiology of Charnoly body and charnolosome -- Charnoly body as a novel biomarker of cell injury -- Charnoly body as a novel biomarker of compromised mitochondrial bioenergetics (biomarkers of CMB; free radical-induced CB molecular pathogenesis) -- Antioxidants prevent Charnoly body formation, augment charnolophagy, and stabilize charnolosome to enhance mitochondrial bioenergetics and intracellular detoxification (therapeutic potential of antioxidants in response to different -- Stages of a free radical attack) -- Metallothioneins inhibit charnoly body formation and confer structural and functional stability to charnolosome (therapeutic potential of metallothioneins (MTS) as CB antagonists; therapeutic potential of (MTS) as charnolosome (CS) stabilizers) -- The Charnoly body : a novel biomarker of mitochondrial bioenergetics -- Clinical significance of Charnoly body as a biomarker of compromized mitochondrial bioenergetics in multidrug resistant diseases -- Development of novel charnolopharmacotherapeutics in pharmaceutical industry by flow cytometric analysis -- Charnoly body as a novel biomarker in nanomedicine (Charnoly body, charnolophagosome, and charnlosome as potential nanotheranostic biomarkers in evidence based personalized medicine) -- Clinical significance of mitochondrial bioenergetic and Charnoly body in evidence based personalized nanotheranostics -- Translational multimodality neuroimaging of Charnoly body, charnolophagy, and charnolosome for personalized theranostics of chronic MDR diseases -- Pet radiopharmaceuticals and surface plasmon resonance spectroscopy for Charnoly body and micro-RNA based personalized theranostics -- Therapeutic potential of stem cells from different biological sources as Charnoly body anagonists, charnolophagy agonists, and charnolosome stabilizers -- Charnolopharmacotherapeutics of chronic multidrug resistant diseases by metallothionein-induced hypoxia inducible factor-1 -- Clinical significance of disease-specific Charnoly body formation -- Charnoly body in fetal alcohol syndrome -- Charnoly body in nicotinism -- Charnoly body in ZIKV disease -- Charnoly body in malnutrition -- Charnoly body in drug addiction and other chronic multi-drug-resistant diseases (therapeutic potential of MTS) -- Charnoly body in cardiovascular diseases -- Charnoly body in stroke -- Charnoly body in traumatic brain injury -- Charnolopharmacotherapy of neurodegenerative and other diseases.…”
Taylor & Francis
OCLC metadata license agreement